Open Dialogue About Complementary Alternative Medicine (CAM) Integrated in Conventional Oncology Care

• ClinicalTrials.gov Identifier: NCT03857776
• Recruitment Status: Completed
• First Posted: February 28, 2019
• Last Update Posted: April 29, 2021
• Sponsor: Vejle Hospital
• Information provided by (Responsible Party): Vejle Hospital

Study Description

Brief Summary:

The purpose of this phase two parallel-group randomized controlled trial is to assess the efficacy of open dialogue about CAM integrated in conventional oncology care. The investigators hypothesize that patients in the intervention group participating in a scheduled open dialogue with a nurse specialist about CAM will experience better physical and mental health compared to patients in the control group receiving standard care alone.

Condition or disease	Intervention/treatment	Phase
Cancer	Other: Open dialogue about complementary alternative medicine; Other: Standard care	Not Applicable

Detailed Description:

Patients randomized to the intervention group will participate in a scheduled open dialogue about CAM with a specialist nurse, who has completed the Fellowship in Integrative Medicine at the University of Arizona. This is a training program for health professionals in empowering individuals and communities to optimize health and well-being through evidence-based, sustainable and integrative approaches. The open dialogue will be based on the fundamentals of person-centered care according to this program and include patient preferences and wishes, reliable information and counselling and advice about the potential risks and benefits of using CAM as an adjunct to conventional oncology care.

All dialogue, each lasting approximately 60 minutes, will be conducted by the same nurse as soon as possible and at the latest two weeks after enrolment. According to patient needs and wishes there may be a follow-up dialogue over the telephone or in the Oncology Outpatient Clinic. The potential second dialogue is estimated to last approximately 30 minutes.

Participants in the control group will receive standard information including reference to www.KABcancer.dk, which is a website presenting research on CAM, including information about its potential effects and outcomes.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 112 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: A Phase Two Parallel-group Randomized Controlled Trial Assessing the Efficacy of Open Dialogue About Complementary Alternative Medicine (CAM) Integrated in Conventional Oncology Care
• Actual Study Start Date: April 5, 2019
• Actual Primary Completion Date: May 24, 2020
• Actual Study Completion Date: May 24, 2020

Arms and Interventions

Arm	Intervention/treatment
Open dialogue about CAM; Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM. The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue.	Other: Open dialogue about complementary alternative medicine; 1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
Standard care; Standard care including referral to a homepage about complementary alternative medicine	Other: Standard care; Standard care including referral to a homepage about CAM

Outcome Measures

Primary Outcome Measures :

1. Difference in frequency of adverse events grade 3-4 between the two arms [ Time Frame: 8 weeks after enrolment ]
   Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAEv5)

Secondary Outcome Measures :

1. Difference in patient reported quality of life between the two arms [ Time Frame: At baseline and after 12 and 24 weeks ]
   Quality of life will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30). The EORTC is composed of both multi item scales and single item measures. These include five functional scales, three symptom scales, a global health status and six single items. All of the scales and single items measures range in score from 0 to 100. A high score for functional scale represents a high/health level of functioning. A high score for the global health status represents a high quality of life. A high score for a symptom scale represents a high level of symptomatology/problems
2. Difference in patients' evaluation of received information between the two arms [ Time Frame: At baseline and after 12 and 24 weeks ]
   Evaluation of received information will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Information Questionnaire (EORTC QLQ-INFO25).
3. Difference in patient reported degree of anxiety and depression between the two arms [ Time Frame: At baseline and after 12 and 24 weeks ]
   Anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS)
4. Difference in frequency of adverse events grade 3-4 between the two arms [ Time Frame: At baseline and after 12 and 24 weeks ]
   Frequency of adverse events grade 3-4 will be measured by using Common Terminology Criteria for Adverse Events (CTCAEv5)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age 18 or more
• Speaks and reads Danish
• Diagnosed with a new primary cancer or a relapse of cancer within the last 3 months
• Planned or initiated medical oncology treatment at the Department of Oncology, Vejle Hospital
• At least two months of oncology treatment is realistic based on clinical assessment
• Life expectancy of at least six months
• Informed consent

Exclusion Criteria:

-Participation in other trials

Contacts and Locations

Locations

Denmark

Vejle Hospital

Vejle, Denmark, 7100

Sponsors and Collaborators

Vejle Hospital

Investigators

• Study Chair: Lars Henrik Jensen; Department of Oncology, Vejle Hospital

More Information

• Responsible Party: Vejle Hospital
• ClinicalTrials.gov Identifier: NCT03857776
• Other Study ID Numbers: CAMONCO
• First Posted: February 28, 2019
• Last Update Posted: April 29, 2021
• Last Verified: April 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Vejle Hospital:

Randomized controlled trial; Neoplasm; Communication; Complementary medicine; Integrative care; Integrative medicine